These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32127832)

  • 61. Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Cornejo-Estrada A; Nieto-Rodríguez C; León-Figueroa DA; Moreno-Ramos E; Cabanillas-Ramirez C; Barboza JJ
    Children (Basel); 2023 Jan; 10(2):. PubMed ID: 36832337
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Long Y; Zhang Y
    Ir J Med Sci; 2023 Dec; 192(6):2809-2814. PubMed ID: 37036569
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.
    Albaker W; Al Sheikh M; Albakr A; Alkhafaji D; Al Besher E; Al-Hariri M
    Int J Gen Med; 2021; 14():8643-8650. PubMed ID: 34849008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potential contributors to variation in weight-loss response to liraglutide.
    Webster CM; Mittal N; Dhurandhar EJ; Dhurandhar NV
    Obes Rev; 2023 Jul; 24(7):e13568. PubMed ID: 37069131
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Okechukwu CE
    N Engl J Med; 2021 Aug; 385(6):572-573. PubMed ID: 34347963
    [No Abstract]   [Full Text] [Related]  

  • 66. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    de Souto Barreto P; Rolland Y
    N Engl J Med; 2021 Aug; 385(6):572. PubMed ID: 34347962
    [No Abstract]   [Full Text] [Related]  

  • 67. Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.
    Brady C; Shaikh MG
    Arch Dis Child Educ Pract Ed; 2022 Jun; 107(3):232. PubMed ID: 32988963
    [No Abstract]   [Full Text] [Related]  

  • 68. Liraglutide for Adolescents with Obesity.
    Maljaei MB; Bahreini A
    N Engl J Med; 2020 Sep; 383(12):1193. PubMed ID: 32937057
    [No Abstract]   [Full Text] [Related]  

  • 69. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
    Kelly AS; Auerbach P; Barrientos-Perez M; Gies I; Hale PM; Marcus C; Mastrandrea LD; Prabhu N; Arslanian S;
    N Engl J Med; 2020 May; 382(22):2117-2128. PubMed ID: 32233338
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
    Kushner RF; Calanna S; Davies M; Dicker D; Garvey WT; Goldman B; Lingvay I; Thomsen M; Wadden TA; Wharton S; Wilding JPH; Rubino D
    Obesity (Silver Spring); 2020 Jun; 28(6):1050-1061. PubMed ID: 32441473
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The limits and challenges of antiobesity pharmacotherapy.
    Gadde KM; Atkins KD
    Expert Opin Pharmacother; 2020 Aug; 21(11):1319-1328. PubMed ID: 32292094
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liraglutide for management of adolescent obesity.
    Kelishadi R
    Nat Rev Endocrinol; 2020 Aug; 16(8):405-406. PubMed ID: 32514092
    [No Abstract]   [Full Text] [Related]  

  • 74. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liraglutide for Adolescents with Obesity.
    Amarin JZ; Dahbour AS; Zayed AA
    N Engl J Med; 2020 Sep; 383(12):1193. PubMed ID: 32937056
    [No Abstract]   [Full Text] [Related]  

  • 76. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
    Page LC; Freemark M
    Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
    N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.